Immutep unveiled Phase 2b TACTI-003 trial results for eftilagimod alpha combined with KEYTRUDA in treating first-line metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression.
The combination demonstrated a 26.9% overall response rate in 26 assessable patients, indicating treatment advancement for this challenging subgroup.
The study suggests that efti with KEYTRUDA could broaden treatment-responsive patient populations sans chemotherapy.
Further trial data, including complete response rates, is eagerly awaited in early 2024.